+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 3Years - 11Years
All Genders
ID06948214

Randomized, Double-Blind Study of Daily Oral LUM-201 Versus Placebo in Children Aged 3 to 11 With Growth Hormone Deficiency A Multicenter 12-Month Phase 3 Trial Evaluating Safety and Effectiveness

Led by Lumos Pharma · Updated on 2026-10-19

150

Participants Needed

55

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating LUM-201 as a treatment for Pediatric Growth Hormone Deficiency PGHD in children who have not previously received treatment. This multinational Phase 3 clinical trial aims to assess the safety and effectiveness of daily oral LUM-201 and to validate a predictive marker to identify children most likely to respond to this therapy. The study compares daily oral doses of LUM-201 at 1.6 mgkg to a matched placebo, in a randomized, double-blind manner. Participants are prepubertal children aged 3 to 11 years, treated over a 12-month period. The trial measures growth outcomes while monitoring safety and response to the medication. Participants undergo regular assessments including growth measurements and hormone evaluations over the year-long treatment. The primary outcome is annualized height velocity after 12 months of treatment with LUM-201 compared to placebo. Safety is monitored throughout the trial, with follow-up continuing until study completion in early 2028.

CONDITIONS

Brief Title

Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency

Research Team

L

Lumos Pharma

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here